- Approval Id
- ea76875c0852c9d0
- Drug Name
- CLAMOX FILM-COATED TABLETS 1G
- Product Name
- CLAMOX FILM-COATED TABLETS 1G
- Approval Number
- SIN16749P
- Approval Date
- 2023-03-29
- Registrant
- GOLDPLUS UNIVERSAL PTE LTD
- Licence Holder
- GOLDPLUS UNIVERSAL PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- TABLET, FILM COATED
- Dosage
- **RECOMMENDED DOSAGE:**
Dosage depends on the age and renal function of the patient and the severity of the infection.
To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of amoxicillin/clavulanic acid is optimised when taken at the start of a meal.
Treatment should not be extended beyond 14 days without review.
Therapy can be started parenterally and continued with an oral preparation.
Amoxicillin/clavulanic acid tablets are not recommended in children of 12 years and under.
_**Adults and Children over 12 years**_
The usual recommended daily dosage is:
**Renal Impairment**
No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 mL/min. The amoxicillin/clavulanic acid 1g tablet should only be used in patients with a creatinine clearance (CrCl) rate of more than 30 mL/min.
**Hepatic Impairment**
Dose with caution; monitor hepatic function at regular intervals.
- Route Of Administration
- ORAL
- Indication Info
- **INDICATIONS:**
Amoxicillin/clavulanic acid is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics.
Amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Amoxicillin/clavulanic acid oral presentations for twice daily dosing, are indicated for short-term treatment of bacterial infections at the following sites:
_Upper respiratory tract infections (including ENT)_ e.g. tonsillitis, sinusitis, otitis media.
_Lower respiratory tract infections_ e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.
_Genito-urinary tract infections_ e.g. cystitis, urethritis, pyelonephritis.
_Skin and soft tissue infections_ e.g. boils, abscesses, cellulitis, wound infections.
_Bone and joint infections_ e.g. osteomyelitis.
_Dental infections_ e.g. dentoalveolar abscess, pericoronitis, acute periodontitis.
_Other infections_ e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Susceptibility to amoxicillin/clavulanic acid will vary with geography and time (see _Pharmacological Properties, Pharmacodynamics_ for further information – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
- Contraindications
- **CONTRAINDICATIONS:**
Amoxicillin/clavulanic acid is contraindicated in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins.
Amoxicillin/clavulanic acid is contraindicated in patients with a previous history of amoxicillin/clavulanic acid -associated jaundice/hepatic dysfunction.
- Atc Code
- J01CR02
- Atc Item Name
- amoxicillin and beta-lactamase inhibitor
- Pharma Manufacturer Name
- GOLDPLUS UNIVERSAL PTE LTD
- Company Detail Path
- /organization/goldplus-universal-pte-ltd
